ClinicalTrials.gg
Active, not recruitingNCT06567769Updated Sep 8, 2026

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

A Phase 1 interventional study of GC1130A in Sanfilippo Syndrome Type A, sponsored by GC Biopharma Corp. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by GC Biopharma Corp · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
12 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.

Planned enrollment
17th of 23
9 · median 17
Started
2024
with 2 others
Phase 1
Only one
of the 43
Primary completion
2027-06
later than 5 of 14 live
Registered
39th of 43
by date

Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 17th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 1, reaches primary completion later than 5 of the 14 other live ones, and was the 39th registered.

Mucopolysaccharidosis III

58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.

Browse Mucopolysaccharidosis III studies →

Open to participants now

12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 12 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Mucopolysaccharidosis III with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).

03

Conditions studied

  • Sanfilippo Syndrome Type A

Keywords

  • Mucopolysaccharidosis Type III Subtype A
  • MPS IIIA
04

Who can participate

Ages eligible
12 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with documented MPS IIIA diagnosis
  • Participants aged ≥ 12 months and ≤ 18 years

Exclusion criteria

Exclusion Criteria:

  • Participants with significant non-MPS IIIA related central nervous system impairment
  • Participants with previous complication from intraventricular drug administration
  • Participants with for MRI scans and for neurosurgery
  • Participants that received treatment with any drug or a device intended as a treatment for MPS IIIA within 30 days or 5 half-lives prior to the study
  • Participants that received a hematopoietic stem cell or bone marrow transplant or received gene therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Drug: GC1130A

  • Experimental
    Cohort 2

    Drug: GC1130A

  • Experimental
    Cohort 3

    Drug: GC1130A

Interventions

  • DrugGC1130A

    ICV injection

06

What researchers measure

Primary outcomes

  1. Incidences and characteristics of adverse events

    Time frame: up to 108 weeks

Secondary outcomes

  1. Maximum concentration in cerebrospinal fluid (CSF)

    GC1130A PK parameters

    Time frame: up to 104 weeks

  2. Area under the concentration-time curve in CSF

    GC1130A PK parameters

    Time frame: up to 104 weeks

  3. Maximum concentration in serum

    GC1130A PK parameters

    Time frame: up to 104 weeks

  4. Area under the concentration-time curve in serum

    GC1130A PK parameters

    Time frame: up to 104 weeks

  5. Change from baseline in CSF heparan sulfate concentration

    Time frame: up to 104 weeks

  6. Change from baseline in serum heparan sulfate concentration

    Time frame: up to 104 weeks

  7. Incidence of anti-drug and neutralizing antibodies of GC1130A in CSF

    Time frame: up to 104 weeks

  8. Incidence of anti-drug and neutralizing antibodies of GC1130A in serum

    Time frame: up to 104 weeks

  9. Change from baseline in raw scores in cognitive domain of Bayley Scales of Infant and Toddler Development Scores-3rd edition (BSID-III)

    Time frame: up to 104 weeks

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 23, 2024
StartActual
Nov 21, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06567769
Lead sponsor
GC Biopharma Corp
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Nov 21, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion